Bill Gates Discusses Meeting with Trump Musks DOGE and Childhood in WSJ Interview Ahead of Source Code Book Gold Under Pressure as Feds Waller Flags Potential Rate Hike Amid Iran War Energy Shock China Emphasizes APEC Cooperation as Trade Minister Misses Opening Session Due to Urgent Business Equity Risk Premium Narrows as Investor Bullishness Persists Zscaler ZS ZeroTrust Strategy Attracts Attention Amid Turnover Narrative Americans Feel Inflations Bite This Holiday Weekend Heres Where Prices Are Rising Most MPLT Q1 2026 Earnings WiderthanExpected Loss Reflects Continued Development Spending Inuvo Q1 2026 Earnings Deep Profit Beat Drives Strong Stock Reaction FFWM Q4 2025 Earnings EPS Significantly Misses Estimates Stock Rises 243 PCVX Q1 2026 Earnings EPS Miss Reflects RD Intensity Clinical Progress Remains Key Concentrix CNXC Q1 2026 Earnings EPS Miss and Revenue NonDisclosure Weigh on Sentiment CYTK Q1 2026 Earnings ClinicalStage Biotech Beats EPS Estimates but Stock Slips Redwood Trust Senior Notes RWTP Slide Marginally as Yield Attracts Cautious Traders Polaryx Therapeutics PLYX Slips 863 as Biotech Volatility Resurfaces Key Support Levels in Focus Ardelyx ARDX Stock Sees Modest Gain Approaches Resistance at 656 Athene Holding Debentures ATHS Hold Steady Near Resistance Amid Low Volatility Instil Bio Inc TIL Holds Steady Near Key Support After Modest Uptick Trumps Very Disloyal Jab Texas Senator John Cornyn Faces Political Battle Amid 109 Million Ad Spending Calix Inc Q1 2026 Earnings EPS Meets Estimates Amid Steady Execution Alto Ingredients ALTO Gains 377 as Stock Approaches Resistance Zone Indaptus Therapeutics INDP Surges 15 Biotech Stock Breaks Above Key Resistance SouthState Bank SSB Edges Lower as Traders Assess Support Levels Five Below FIVE Slides 23 as Support Levels Come Into Focus Harvard Bioscience Slips as Traders Assess Support Levels HBIO Down Nearly 3 Apimeds Pharmaceuticals APUS Slides 423 Support Level in Focus UGI Corporation UGI Edges Lower Holding Above Key Support Zone Prime Medicine PRME Surges Over 11 as Gene Editing Stock Finds Support Near 313